{
    "relation": [
        [
            "",
            "QVA149",
            "Fluticasone/Salmeterol"
        ],
        [
            "Description",
            "Participants received indacaterol and glycopyrronium (QVA149) and placebo to fluticasone/salmeterol.",
            "Participants received fluticasone/salmeterol and placebo to indacaterol and glycopyrronium (QVA149)."
        ]
    ],
    "pageTitle": "QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01315249?sect=X4g015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990900.28/warc/CC-MAIN-20150728002310-00135-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 871191515,
    "recordOffset": 871175806,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups A total of 523 patients were randomized. A total of 522 patients (99.8%) were included in the Full analysis Set (FAS) and Safety set. One patient was excluded who was randomized in error and did not receive study medication. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details All eligible patients were randomized to one of the 2 arms in a 1:1 ratio for 26 weeks of treatment. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: indacaterol and glycopyrronium (QVA149) Drug: Placebo to fluticasone/salmeterol Drug: fluticasone/salmeterol Drug: Placebo to indacaterol and glycopyrronium (QVA149) Interventions: Chronic Obstructive Pulmonary Disease (COPD)",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 QVA149 \u00a0 \u00a0 Fluticasone/Salmeterol \u00a0 STARTED \u00a0 \u00a0 259 \u00a0 \u00a0 264 \u00a0 COMPLETED \u00a0 \u00a0 215 \u00a0 \u00a0 217 \u00a0 NOT COMPLETED \u00a0 \u00a0 44 \u00a0 \u00a0 47 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 22 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 26 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 11 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 10 \u00a0 Protocol Violation \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 8 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}